Targeted drug cabozantinib tested in Hard-to-Treat prostate cancer
NCT ID NCT04631744
First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 20 times
Summary
This study tested the drug cabozantinib in men with a type of advanced prostate cancer that no longer responds to hormone therapy. It focused on patients whose tumors had certain gene changes or had spread to the liver. The goal was to see if the drug could slow cancer growth, but the trial was stopped early after enrolling only 4 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.